Lyvelsa 20Mg Tablet 14

LYVELSA 20MG TABLET 14 interacts with the following medicines:

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): Concomitant use is contraindicated due to increased finerenone levels and risk of severe hyperkalaemia.
• Moderate or weak CYP3A4 inhibitors (e.g., erythromycin, fluconazole): Concomitant use may increase potassium levels; serum potassium should be monitored closely.
• Strong or moderate CYP3A4 inducers (e.g., rifampicin, carbamazepine): Concomitant use may reduce effectiveness and should be avoided.

LYVELSA 20MG TABLET 14 may interact with the following foods:

• Grapefruit and grapefruit juice:  Grapefruit and grapefruit juice should be avoided, as they can increase finerenone levels and raise the risk of side effects.

LYVELSA 20MG TABLET 14 may interact with the following conditions:

• Adrenal insufficiency: Use is contraindicated due to altered mineralocorticoid balance.
• Hyperkalaemia: Existing high potassium levels may worsen during treatment.

The recommended dose of LYVELSA 20MG TABLET 14 is determined by your doctor based on kidney function and serum potassium levels. Dose adjustments may be required during treatment depending on the condition.
 

In case of overdose, symptoms such as low blood pressure, dizziness, electrolyte imbalance, or abnormal heart rhythm may occur. Seek immediate medical attention if overdose is suspected.
 

If a dose is missed, take it as soon as remembered on the same day. If it is already the next day, skip the missed dose and continue with the regular schedule. Do not take a double dose.